Profits from Teva's (TEVA 1.56%) flagship drug, Copaxone, may be in jeopardy. The company just lost a major court case, invalidating a key patent, that will allow generic versions of the multiple sclerosis drug to market by May 2014, a full 16 months early. In this video, Motley Fool health-care analyst David Williamson discusses just how much this compressed timeline is going to hurt Teva and what he'll be looking for with the company going forward.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.